#HIV research

Take a survey on HIV cure research.

It’s just one episode of “HIV Matters,” a (free!) podcast series from the University of North Carolina’s Department of Medicine.

An estimated 7,760 HIV-positive U.S. residents were diagnosed with cancer in 2010.

People who have a low CD4 count, have cirrhosis and take certain hep C drug regimens are less likely to be cured.

The CDC reports that PrEP use is low among Blacks and Latinos.

This long-acting drug is linked to undetectable viral loads in former prisoners with substance use disorders.

Robert R. Redfield, MD, is a longtime HIV researcher. But he’s also controversial.

Merck’s investigational antiretroviral could one day be dosed only weekly among HIV-negative humans.

Scientists tested the effects of the broadly neutralizing antibody PGT121 and the immune-stimulating agent GS-9620 in monkeys.

Two men claim they developed bone and kidney problems after taking TDF. A related class action lawsuit has also been filed.

Like HIV, HTLV-1 can be transmitted through blood and sex. It weakens the immune system and can cause death.

For example: Hep C cures have meant fewer people to treat and fewer transmissions to potential patients.

A three-month vaginal ring could help prevent HIV in women.

A star-shaped drug capsule could permit weekly dosing of HIV meds.

Research shows that CAR-T cells could one day help cure HIV in humans.

People living with HIV are not getting vaccinated for hepatitis B.